Sheffield Traffic Light Drugs List
October 2026

Please also check the SY Traffic Light Drug List

Note: the BNF numbering system is based on the BNF legacy

Refer to the user guide for classification rationale

Remember : Control + F (see user guide for how to) to search this list

BNF Section	Drug	Rational : see introduction	Notes	Relevant links
4.10.1	**Acamprosate**		If initiated in primary care, to be prescribed by a GP/prescriber with special interest OR experience in alcohol relapse prevention and in conjunction with an offer of psychological interventions. See the prescribing guideline for more information.	
7.4.5	**Alprostadil**	**1, 2**	If SLS criteria not met: a GP may provide a private prescription (detailed in HSC 1999/148) See also entry in amber section.	
7.4.5	**Alprostadil**	**1**	SLS criteria applies - prescriptions may be issued for patients eligible for NHS treatment (as per SI 2004 No 629), otherwise RED. Note - Patients with Severe Distress are not covered by SLS criteria (as detailed in HSC 1999/177).	HSC 1999/177
2.3.2	**Amiodarone**	**1, 2, 3**	Amiodarone SCG	
4.2.1	**Amisulpride**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
8.3.4.1	**Anastrozole**	**1, 2**	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on prescribing for a specified duration, for advice on drug management see: Referral and Management Guidelines for Breast Cancer. See also, section on ibandronic acid.	
OTC Preparations	**Anti-fungal nail paints**	**4**	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	
4.2.1	**Aripiprazole**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose. ***For immediate release injection see SY IMOC TLDL.***	SY IMOC TLDL
4.2.3	**Asenapine**	**1**	SHSC have also stated that they would not be routinely initiating prescriptions.	
4.4	**Atomoxetine**	**1, 2**	SCG for ADHD in Children and Adults	
	Avacopan	**1, 5**	NHSE commissioned.	NICE TA825
For treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure	**Avatrombopag**	**1, 5**		NICE TA626
10.1.3	**Azathioprine**	**1, 5**	When no agreed SCP available.	
10.1.3	**Azathioprine**	**1, 2, 3**	Azathioprine and Mercaptopurine SCP	
4.2.1	**Benperidol**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
	Berotralstat	**1, 5**	NHSE commissioned.	NICE TA738
8.1	**Bexarotene**	**1, 5**	is	
2.12	**Bezafibrate**	**1**	For hypertriglyceridemia and/or mixed dyslipidaemia; however, use in this cohort of patients would usually be on the initiation or recommendation of a lipid clinic specialist.	
8.3.4.2	**Bicalutamide**	**1, 2**	Hormonal Management of Prostatic Cancer SCP	
5.3.3.2	**Boceprevir** for the treatment of genotype 1 chronic hepatitis C	**1, 5**	http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c-cirrhosis-policy-statmnt-0615.pdf.	NICE TA253

13.6.3	**Brimonidine tartrate (Mirvaso®)**	**1**	For management of rosacea: See Drug Safety Alerts on risk of exacerbation of rosacea MHRA	See MHRA update on systemic cardiovascular effects
4.8.1	**Brivaracetam**	**1**	Epilepsy in Children SCG	
4.10.2	**Bupropion Hydrochloride**	**5**	Clients over 12 years and non-pregnant women should be signposted to the commissioned Stop Smoking service http://sheffield.yorkshiresmokefree.nhs.uk/	
8.1	**Busulfan**	**1, 5**	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medicines where a shared care protocol exists.	
6.1.2.3	**Canagliflozin**			NICE TA315
8.1	**Capecitabine**	**1, 5**	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medicines where a shared care protocol exists.	
10.1.3	**Certolizumab Pegol**	**1, 5**		
8.1	**Chlorambucil**	**1, 5**	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medicines where a shared care protocol exists.	
4.2.1	**Chlorpromazine hydrochloride**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
8.2.2	**Ciclosporin**	**1**	Unless disease specific shared care arrangement in place (See SY IMOC TLDL). Regular monitoring required. See: Common blood monitoring.	SY IMOC TLDL
	Co-enzyme Q10	**3**	For all indications **except Friedreich's ataxia; See Co-enzyme Q10 in SY IMOC TLDL)**	SY IMOC TLDL
2.8.2	**Dabigatran etexilate**	**1, 5**	for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. Note: full course to be provided by secondary care.	NICE TA157
6.7.2	**Danazol**	**1, 2, 3**	For unlicensed indications and more details, see CAS Supply Disruption Alert (29 May 2020): Note to prescribers: as there can be a delay in obtaining supplies; please allow 2 weeks for communnity pharmacy to source the unlicensed product.	
10.2.2	**Dantrolene sodium**	**1, 2, 3**		
7.4.6	**Dapoxetine**	**1, 2**	To be prescribed only when all the criteria specified in the SPC are met. A maximum supply of 6 tabs per month is advised by the Sheffield APG.	
9.1.3	**Darbepoetin alfa**	**1, 5**	Renal Anaemia, specialised commissioning.	
8.3.4.2	**Degarelix**	**1, 2**	Hormonal Management of Prostatic Cancer SCP	
5.3.1	**Didanosine**	**1, 5**	NHSE commissioned.	
3.7	**Dornase Alfa**	**5**	Specialised commissioning. To be prescribed by cystic fibrosis services.	
6.1.2.3	**Dulaglutide**	**1**		
2.8.2	**Edoxaban** for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation		Local guidelines for the prevention of stroke in non-valvular atrial fibrillation. See Amber section for other indication.	NICE TA355
2.8.2	**Edoxaban** for the treatment and secondary prevention of deep vein thrombosis and pulmonary embolism	**1**	Note: treatment of DVT and PE will be initiated in secondary care. See Green section for other indication.	NICE TA354.
9.4.2	**Enteral Feeding Solutions**	**1**	When dietetic advice is provided. See appendix 2 of the BNF for full list.	
2.5.5.2	**Entresto® (sacubitril valsartan)**	**1, 2, 3**	ONLY to be transferred to a GP when patient has been up titrated and on a stable, optimal dose.	NICE TA388
2.2.3	**Eplerenone**	**1**	For patients intolerant of spironolactone due to gynaecomastia.	
8.1	**Estramustine phosphate**	**1, 5**	Should not be prescribed in primary care as an oral anticancer medication, in line with NPSA Alert. Exceptions include oral anti cancer medicines where a shared care protocol exists.	
4.8.1	**Ethosuximide**	**1**	Epilepsy in Children SCG	NICE CG137
8.3.4.1	**Exemestane**	**1, 2**	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on prescribing for a specified duration, for advice on drug management see: Referral and Management Guidelines for Breast Cancer. See also, section on ibandronic acid.	
6.1.2.3	**Exenatide**	**1**		
10.1.4	**Febuxostat**		Now first line with allopurinol.	NICE NG219
2.12	**Fenofibrate**	**1**	For hypertriglyceridemia and/or mixed dyslipidaemia; however, use in this cohort of patients would usually be on the initiation or recommendation of a lipid clinic specialist.	

5.1.7	**Fidaxomicin**	**1**	If prescribed in line with NICE NG199 as a second line antibiotic for a first episode of mild, moderate or severe C.difficile infection if vancomycin ineffective or for a further episode (see NICE guidance). Following specialist recommendation, fidaxomicin may be prescribed by a primary care clinician. See also vancomycin (oral) in Green section.	NICE NG199
4.2.1	**Flupentixol**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
8.3.4.1	**Fulvestrant**	**1, 2**	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on prescribing for a specified duration, for advice on drug management see: Referral and Management Guidelines for Breast Cancer. See also, section on ibandronic acid.	
	gammaCore	**1**		MTG 46
8.3.4.2	**Goserelin**	**1, 2**	Hormonal Management of Prostatic Cancer SCP. NB see also goserelin in endocrine management of breast cancer.	
8.3.4.1	**Goserelin**	**1, 2**	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on prescribing for a specified duration, for advice on drug management see: Referral and Management Guidelines for Breast Cancer. See also, section on ibandronic acid. See also goserelin in the management of prostatic cancer.	
4.4	**Guanfacine**	**1, 2, 3**	Shared Care for the Management of Prescribing for ADHD	
4.2.1	**Haloperidol**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
10.1.3	**Hydroxychloroquine**	**1, 2, 3**	Hydroxychloroquine Prescribing in Adults SCG	
6.6.2	**Ibandronic acid**	**1, 2**	Prescribing Guideline - Ibandronic acid in post menopausal women with breast cancer– unlicensed indication. Note, use only ibandronic 50mg tablets.	See also Referral and Management of Breast Cancer.
OTC Preparations	**Ibuprofen 200mg - 400mg for acute pain in adults**	**4**	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	
2.12	**Icosapent ethyl**	**1**		NICE TA805
2.12	**Inclisiran**		For secondary prevention of cardiovascular disease in line with NICE TA733 - see SY Lipid Optimisation Guidance.	NICE TA733
Respiratory devices	**Inspiratory Muscle Trainer (IMT) Device**. e.g. Powerbreathe Medic, Phillips Threshold IMT.	**1**	See IMT prescribing guidance	
6.1.1.1	**Insulin aspart (Fiasp®)**	**1**	For children only, as identified by the secondary care specialist. The first prescription can, with agreement of the primary care clinician, be issued in primary care, subject to receiving a detailed communication, from the specialist, which includes information on the ongoing support and monitoring that secondary care will provide.	
6.1.2	**Insulin degludec**	**1, 2, 3**	For use in restricted patient populations. Please take care with the strength of insulin degludec, see: MHRA guidance. Also see amber section for Xultophy®.	
6.1.1	**Insulin glargine 300u/ml injection (Toujeo®)**		Please prescribe by brand and take care with the strength of insulin.	See MHRA advice
2.6.3	**Ivabradine**	**1**	TA267 - Ivabradine for treating chronic heart failure.	NICE CG126 Stable angina management
5.3.1	**Lamivudine (including combinations)**	**1, 5**	NHSE commissioned.	
9.5.2.2	**Lanthanum**	**1, 5**	To be prescribed by renal services, specialised commissioning.	
5.3.3	**Ledipasvir with sofosbuvir (Harvoni®)**	**1, 5**	NHSE commissioned.	NICE TA363
10.1.3	**Leflunomide**	**1, 2, 3**	Leflunomide SCP	
8.2.4	**Lenalidomide**	**1**		
8.3.4.1	**Letrozole**	**1, 2**	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on prescribing for a specified duration, for advice on drug management see: Referral and Management Guidelines for Breast Cancer. See also, section on ibandronic acid.	
8.3.4.2	**Leuprorelin**	**1, 2**	Hormonal Management of Prostatic Cancer SCP.	
15.2	**Lidocaine plasters**	**4**	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	NICE CG173
15.2	**Lidocaine plasters**	**1**	Approved by Sheffield Teaching Hospitals for post operative neuropathic pain of chest drain site (thoracic surgery). This is mainly inpatient use but possibly on discharge for short period of time. Not for continued prescribing. Also, see Black and Amber sections.	NICE CG173
15.2	**Lidocaine plasters**	**1, 2, 3**	In exceptional circumstances agreed with pain clinic or palliative care. See prescribing guidance. Also, see Black and Red sections.	NICE CG173
1.6.7	**Linaclotide**		As a third line treatment for moderate to severe irritable bowel syndrome with constipation in adults. See local guidelines.	

4.5	**Liraglutide (Saxenda®)**	**4**	For use outside the NICE TA 664. See also Red and Amber sections.	
6.1.2	**Liraglutide (Victoza®)**	**1**	For Type 2 diabetes in adults:management. See also liraglutide (Victoza®) for children, in Amber section and liraglutide (Saxenda®) in Black section.	NICE NG28
6.1.2	**Liraglutide (Victoza®) for children**	**1, 2**	As third line management in children and young people aged 10 years and over. See also liraglutide / Saxenda in Black section.	
4.4	**Lisdexamfetamine**	**1, 2, 3**	Shared Care / Prescribing Guideline for the management for prescribing in ADHD	NICE TA98
4.2.3	**Lithium carbonate**	**1, 2**	Lithum SCP	
6.1.2.3	**Lixisenatide**	**1**		
4.10.3	**Lofexidine hydrochloride**	**1, 2**	For the treatment of opioid dependence,If advice available from specialist services, and prescribed in accordance with national treatment guidelines – otherwise RED. Local guidelines available for GPs who agree to prescribe.	
4.8.2	**Lorazapam**	**1**	Epilepsy in Adults SCP	NICE CG137
4.8.2	**Lorazapam**	**1**	Epilepsy in Children SCG	NICE CG137
8.1.3	**Mercaptopurine**	**1, 2, 3**	Should not be prescribed in primary care as an oral anticancer medication. Should only be prescribed for inflammatory bowel disease following agreement with a local specialist. Azathioprine and mercaptopurine SCP	
4.10.3	**Methadone**	**1, 5**	As opioid substitution therapy. https://www.shsc.nhs.uk/services/opiates-service-sheffield-treatment-and-recovery-team	
10.1.3	**Methotrexate**	**1, 2, 3**	Methotrexate SCG	
9.1.3.	**Methoxy polyethylene glycol - epoetin beta**	**1, 5**	Nevir	
Prescribing in Ventricular arrhythmias	**Mexiletine**	**1, 4**	Ventricular arrythmias - unlicensed indication not in BNF. For licensed indications see SY IMOC TLDL.	SY IMOC TLDL
2.7.2	**Midodrine**	**1, 2, 3**	Midodrine SCP	
4.7.2	**Morphine orodispersible tablets (Actimorph®)**		Morphine orodispersible tablets (Actimorph®) are an option for use in vulnerable patient groups, to reduce the risk of accidental or intentional overdose; or where there are dexterity issues.	
8.2.1	**Mycophenolate**	**1, 3**	Specialised commissioning; to be prescribed by specialist services for transplant recipients. See also amber section for Adult rheumatology patients with connective tissue disease.	
8.2.1	**Mycophenolate**	**1, 2, 3**	Mycophenolate Mofetil SCG. See Red section for transplant recipients.	
4.6	**Nabilone**	**1, 5**	For intractable nausea and vomiting.	NICE NG144
1.6.6	**Naldemedine**	**1**		NICE TA651
4.10.1	**Nalmefene**	**1, 5**	Sheffield Alcohol Service: https://shsc.nhs.uk/service/sheffield-alcohol-services/	NICE TA325
1.6.6	**Naloxegol**	**1**		NICE TA345
4.10.3	**Naltrexone hydrochloride**	**1, 2**	For the treatment of opioid dependence, If advice available from specialist services, and prescribed in accordance with national treatment guidelines – otherwise RED. Local guidelines available for GPs who agree to prescribe. For alcohol relapse prevention see Green section.	
4.10.3	**Naltrexone hydrochloride**		If initiated in primary care, to be prescribed by a GP/prescriber with special interest OR experience in alcohol relapse prevention and in conjunction with an offer of psychological interventions. See the prescribing guideline for more information.	
10.3.2	**NSAIDs (topical) diclofenac sodium, felbinac, ibuprofen, ketoprofen and piroxicam**	**4**	For self-care. See also entry in Green section.	
10.3.2	**NSAIDs (topical) diclofenac sodium, felbinac, ibuprofen, ketoprofen and piroxicam**		In line with NICE guidance for osteoarthritis. Topical ibuprofen is the Sheffield formulary choice. See also entry in Black section.	NICE NG226
8.3.4.3	**Octreotide**	**1, 2, 3**	Specialist to initiate and stabilise dose.	
4.2.2	**Olanzapine (depot injection)**	**1**	SHSC have stated that they would not be routinely initiating prescriptions.	
4.2.1	**Olanzapine (oral medication only)**	**1, 2**	Specialist to initiate and stabilise dose.	
2.12	**Omega-3-Fatty Acid capsules (e.g.Omacor®, Prestylon® , Nebbaro® and Maxepa®)**	**1**	For hypertriglyceridaemia to prevent acute pancreatitis.	
Respiratory devices	**Oscillating Positive Expiratory Pressure (OPEP) Device** e.g. Acapella®, Aerobika	**1**	See OPEP prescribing guidance	
4.7.2	**Oxycodone and naloxone combination product (Targinact®)**	**4**	See Sheffield STOP list for full details and note circumstances where prescribing may be appropriate.	

10.1.3	**Penicillamine**	**1, 2**	For the treatment of Wilsons Disease and Cystinuria in adults.	
4.9.1	**Pergolide**	**1**	Parkinson's Disease SCP	
4.2.1	**Pericyazine**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	**Perphenazine**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
13.5.3	**Pimecrolimus (topical)**		When a prescriber is GPwSI in dermatology, or on their recommendation, or is competent in prescribing in dermatological conditions	NICE TA82
4.2.1	**Pimozide**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	**Pipotiazine Palmitate**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
2.9	**Prasugrel**	**1**		NICE TA317
4.2.1	**Prochlorperazine**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	**Promazine hydrochloride**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
1.6.7	**Prucalopride**	**1, 2**	See prescribing guidance to support specialist initiation and ongoing prescribing in primary care.	
4.2.1	**Quetiapine**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
4.2.1	**Quetiapine modified release**	**1**	SHSC have stated that they would not be routinely initiating prescriptions.	
2.6.3	**Ranolazine**	**1**	Cardiologist initiation in line with NICE CG126.	NICE CG126
A 2.4.2 Vitamin and mineral supplements	**Renavit®**	**1**	Dietary management of water soluble vitamin deficiency in renal patients receiving dialysis.	
5.1.7	**Rifaximin (Targaxan®)**	**1, 2, 3**	For preventing episodes of overt hepatic encephalopathy. Rifaximin guideline	NICE TA337
4.2.1	**Risperidone**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
2.8.2	**Rivaroxaban** for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation		Local guidelines for the prevention of stroke in non-valvular atrial fibrillation. See Red and Amber sections for other indications.	NICE TA256
2.8.2	**Rivaroxaban 2.5mg tablets** for patients with coronary artery disease (CAD) or peripheral artery disease (PAD) at high risk of ischaemic events.	**1**	See Red and Green sections for other indications.	NICE TA607
2.8.2	**Rivaroxaban 2.5mg tablets** for preventing adverse outcomes after acute management of acute coronary syndrome	**1**	See also local guidelines. Note: treatment will be initiated in secondary care. See Red and Green sections for other indications.	NICE TA335
2.8.2	**Rivaroxaban** for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism	**1**	See Red and Green sections for other indications.	NICE TA261
2.8.2	**Rivaroxaban** for treating pulmonary embolism and preventing recurrent venous thromboembolism	**1**	See Red and Green sections for other indications.	NICE TA287
2.8.2	**Rivaroxaban:** Prophylaxis of venous thromboembolism following hip and knee replacement surgery. Note: full course to be provided by secondary care.	**1, 5**	See Amber and Green sections for other indications.	NICE TA170
3.3.3	**Roflumilast**	**1**		NICE TA461
6.6.2	**Romosozumab**	**1, 5**		NICE TA791
5.3.1	**Saquinavir**	**1, 5**	NHSE commissioned.	
6.1.2.3	**Semaglutide (Ozempic®) and (Rybelsus®) for Type 2 diabetes mellitus**	**1**	See SY IMOC TLDL (listed RED pending pathway for primary care use) for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease (NICE TA1152) and for managing overweight or obesity (NICE TA875). *New formulation Wegovy tablets TL GREY on SY IMOC list for weight management.*	Type 2 diabetes in adults NICE NG28
5.3.3.2	**Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C.**	**1, 5**	http://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/06/hep-c-cirrhosis-polcy-statmnt-0615.pdf	NICE TA331
8.2.2	**Sirolimus**	**1, 5**	NHSE commissioned.	
4.1.1	**Sodium Oxybate**	**3**	In **adults, not** previously treated with sodium oxybate for narcolepsy with cataplexy. See red section for children and for adults who have transitioned from children's to adult services and have already been prescribed this drug for narcolepsy.	
6.5.1	**Somatropin (Adults)**	**1, 2**	The treatment of Adults with Growth Hormone (Somatropin)SCG	
6.5.1	**Somatropin (Children)** Human growth hormone (somatropin) for the treatment of growth failure in children	**1, 2**	The treatment of Children with Recombinant Human Growth Hormone SCG	NICE TA188
5.3.1	**Stavudine**	**1, 5**	NHSE commissioned.	
6.6.2	**Strontium Ranelate**	**1**		

1.3.3	**Sucralfate**	**1**	Only on specialist advice for licenced and off-label indications, which include: **in highly selected cases with severe refractory oesophageal ulceration with dysphagia and bleeding and as a temporary measure to help with post banding bleeding in varices.** Review after 8-12 weeks of continued use.	
10.1.3	**Sulfasalazine**	**1, 2, 3**	Sulfasalazine SCG	
4.2.1	**Sulpiride**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
8.2.2	**Tacrolimus (oral)**	**1**	See GREEN section for topical tacrolimus.	
13.5.3	**Tacrolimus (topical)**		When a prescriber is GPwSI in dermatology, or on their recommendation, or is competent in prescribing in dermatological conditions. See also Red section for oral tacrolimus.	NICE TA82
4.7.2	**Tapentadol**	**3**		
6.4.2	**Testosterone: topical preparations for post-menopausal women**	**1, 2, 3**	Topical testosterone replacement therapy in postmenopausal women SCP. See also green section	NICE NG23
6.4.2	**Testosterone: topical preparations for post-menopausal women**		Only where primary care prescriber has knowledge and competency to initiate testosterone without referral to the menopause clinic. See also amber section and Topical testosterone replacement therapy in postmenopausal women SCP	NICE NG23
4.8.1	**Tiagabine**	**1**	Epilepsy in Children SCG	NICE CG137
2.9	**Ticagrelor**	**1**	NICE TA420 for preventing atherothrombotic events after myocardial infarction.	NICE TA236 for the treatment of acute coronary syndromes
2.8.1	**Tinzaparin**	**1**	Unless guidance available.	
5.3.1	**Tipranavir**	**1, 5**	NHSE commissioned.	
10.2.2	**Tizanidine**	**1, 2, 3**	Specialist prescribing for first 4 months.	
5.1.4	**Tobramycin**	**5**	Specialised commissioning. To be prescribed by cystic fibrosis services. See also Amber section for non-cystic fibrosis bronchiectasis indication.	
3.7	**Tobramycin**	**1, 2, 3**	For non-cystic fibrosis bronchiectasis; see SCG. See Red section for cystic fibrosis.	
4.9.1	**Tolcapone**	**1, 5**	NHSE commissioned.	
8.3.4.1	**Toremifene**	**1, 2**	Treatment: Specialist to initiate and stabilise dose and then recommend GP to take on prescribing for a specified duration, for advice on drug management see: Referral and Management Guidelines for Breast Cancer. See also, section on ibandronic acid.	
4.2.1	**Trifluoperazine**	**1, 2**	This includes depot antipsychotics. Specialist to initiate and stabilise dose.	
8.3.4.2	**Triptorelin Acetate 11.25mg**	**1, 2**	Hormonal Management of Prostatic Cancer SCP.	
8.3.4.2	**Triptorelin Pamoate 22.5mg**	**1, 2**	Hormonal Management of Prostatic Cancer SCP.	
5.1.7	**Vancomycin (oral)**		If prescribed in line with NICE NG199 as a first line antibiotic for a first episode of mild, moderate or severe C.difficile infection. See also fidaxomicin in Amber section.	NICE NG199
14.4	**Varicella – Zoster vaccine (Zostavax®)**	**3**	For routine vaccination against herpes zoster (shingles) other than in accordance with the national programme for vaccinating those aged 70 to 79 years.	
5.3.3	**Velpatasvir with sofosbuvir (Epclusa®)**	**1, 5**	NHSE commissioned.	NICE TA430
5.3.3	**Velpatasvir with sofosbuvir and voxilaprevir (Vosevi®)**	**1, 5**	NHSE commissioned.	NICE TA507
4.3.4	**Venlafaxine at doses of 300 mg daily or above**	**1, 2, 3**	Higher doses of venlafaxine have greater potential to exacerbate cardiac arrhythmias and hypertension. See also venlafaxine in green section.	
5.2.1	**Venlafaxine modified and immediate release**		SHSC have stated that they would not be routinely initiating prescriptions for modified release preparations. For **total daily doses of 300mg or above** see Amber section.	
9.6.2	**Vitamin B Compound/Compound Strong/Complex**	**4**	See Sheffield STOP list for full details. Thiamine should be used for patients at high risk of developing Wernicke's encephalopathy.	
4.3.4	**Vortioxetine**		NICE NG222 Depression in adults: treatment and management	NICE TA367 Vortioxetine for treating major depressive episodes
6.1.2.	**Xultophy® (insulin degludec 100 unit per 1 ml , liraglutide 3.6mg per 1 ml)**	**1, 2, 3**	Also see amber section: insulin degludec.	
4.2.1	**Zuclopenthixol Decanoate**	**1, 2**	Depot antipsychotic. Specialist to initiate and stabilise dose.	